NCT07635134

Brief Summary

Primary aldosteronism (PA) is the most common cause of secondary hypertension. Liquid chromatography - tandem mass spectrometry (LC-MS/MS) is more accurate than the traditional radioimmunoassay in measuring aldosterone. This study aims to establish a more precise diagnostic threshold for the oral sodium loading test (OSLT) by using LC-MS/MS to measure urinary aldosterone levels. We will combine the biochemical results of OSLT and other data from healthy volunteers and suspected PA patients to determine a new 24-hour urinary aldosterone threshold. We expect to improve the diagnostic accuracy of PA, helping clinicians identify this curable cause of hypertension earlier and more accurately, and achieving precise treatment.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
800

participants targeted

Target at P75+ for all trials

Timeline
1mo left

Started Apr 2025

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress90%
Apr 2025Aug 2026

Study Start

First participant enrolled

April 1, 2025

Completed
1.2 years until next milestone

First Submitted

Initial submission to the registry

June 3, 2026

Completed
6 days until next milestone

First Posted

Study publicly available on registry

June 9, 2026

Completed
22 days until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 1, 2026

Expected
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

August 1, 2026

Last Updated

June 9, 2026

Status Verified

April 1, 2026

Enrollment Period

1.2 years

First QC Date

June 3, 2026

Last Update Submit

June 3, 2026

Conditions

Keywords

the oral sodium loading testdiagnose

Outcome Measures

Primary Outcomes (1)

  • 24-hour urinary aldosterone levels after a 3-day high-sodium diet

    Two weeks after completing the oral sodium loading test

Study Arms (2)

normal sujects

Healthy volunteers with normal blood pressure and blood potassium levels and no adrenal nodules. These volunteers were used to determine the normal physiological range (lower limit value) of aldosterone inhibition after the test.

Diagnostic Test: The oral sodium loading test

Patients suspected of having primary aldosteronism

Patients suspected of having primary aldosteronism

Diagnostic Test: The oral sodium loading test

Interventions

These subjects underwent a three-day high-salt diet test, during which they consumed an additional 6-10 grams of salt each day. On the third day, tests were conducted on the aldosterone, sodium, potassium and creatinine levels in the 24-hour urine, blood potassium, creatinine, standing aldosterone concentration, plasma renin activity, and the steroid hormone profile.

Patients suspected of having primary aldosteronismnormal sujects

Eligibility Criteria

Age18 Years - 70 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

1)Healthy Controls to establish physiological suppression limits.2) Patients with suspected PA undergo oral sodium loading test to determine the cut-off point.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Peking Union Medical Colledge Hospital

Beijing, Beijing Municipality, 100000, China

RECRUITING

MeSH Terms

Conditions

HyperaldosteronismDisease

Condition Hierarchy (Ancestors)

Adrenocortical HyperfunctionAdrenal Gland DiseasesEndocrine System DiseasesPathologic ProcessesPathological Conditions, Signs and Symptoms

Central Study Contacts

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Target Duration
6 Months
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

June 3, 2026

First Posted

June 9, 2026

Study Start

April 1, 2025

Primary Completion (Estimated)

July 1, 2026

Study Completion (Estimated)

August 1, 2026

Last Updated

June 9, 2026

Record last verified: 2026-04

Data Sharing

IPD Sharing
Will not share

Locations